Showing 1407 results
-
Press release /CHICAGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,509,840 shares of its common stock…
-
Press release /New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving…
-
Story /Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
-
Press release /LIBERTY is the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, and are in need of additional treatment options…
-
Press release /CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has…
-
Press release /CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering…
-
Press release /Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive form of non-alcoholic fatty liver disease There are…
-
Press release /Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs.…
-
Story /Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.